Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Operating Leases: 2019-2024

Historic Operating Leases for Collegium Pharmaceutical (COLL) over the last 6 years, with Dec 2024 value amounting to $5.5 million.

  • Collegium Pharmaceutical's Operating Leases fell 23.89% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 23.89%. This contributed to the annual value of $5.5 million for FY2024, which is 9.55% down from last year.
  • Per Collegium Pharmaceutical's latest filing, its Operating Leases stood at $5.5 million for FY2024, which was down 9.55% from $6.1 million recorded in FY2023.
  • Collegium Pharmaceutical's 5-year Operating Leases high stood at $8.8 million for FY2020, and its period low was $5.5 million during FY2024.
  • In the last 3 years, Collegium Pharmaceutical's Operating Leases had a median value of $6.1 million in 2023 and averaged $6.3 million.
  • Data for Collegium Pharmaceutical's Operating Leases shows a maximum YoY fell of 13.89% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Collegium Pharmaceutical's Operating Leases stood at $8.8 million in 2020, then decreased by 9.29% to $8.0 million in 2021, then decreased by 10.55% to $7.1 million in 2022, then declined by 13.89% to $6.1 million in 2023, then fell by 9.55% to $5.5 million in 2024.